rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Carolyn R. Bertozzi

Director

Company insider

Files Form 4 as: Director, OmniAb; Director, Alnylam Pharmaceuticals; Director, Eli Lilly and.

In numbers

Trades disclosed
35
Buys
0
Sells
0
Bought
$0
Sold
$0
Companies
3
Companies where not an officer
3
First trade
20 Nov 2017
Last trade
17 Jun 2026
Last filed
18 Jun 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
OABI OmniAbDirector · Life-science tools · last 17 Jun 20260 buys · 0 sells
ALNY Alnylam PharmaceuticalsDirector · Biotechnology · last 8 May 20250 buys · 0 sells
LLY Eli Lilly andDirector · Pharmaceuticals · last 16 Nov 20200 buys · 0 sells

Activity over time

Not enough dated trades to draw.

Every trade

TradedCompanyWhatAmount
17 Jun 2026filed 18 Jun 2026OABI OmniAbLife-science toolsSEC FORM 4 Code M—20,000filing
17 Jun 2026filed 18 Jun 2026OABI OmniAboption or derivative · Life-science toolsSEC FORM 4 Code M—20,000 at $0.00filing
17 Jun 2026filed 18 Jun 2026OABI OmniAboption or derivative · Life-science toolsSEC FORM 4 Code A—20,000 at $0.00filing
17 Jun 2026filed 18 Jun 2026OABI OmniAboption or derivative · Life-science toolsSEC FORM 4 Code M—20,000 at $0.00filing
17 Jun 2026filed 18 Jun 2026OABI OmniAboption or derivative · Life-science toolsSEC FORM 4 Code A—20,000 at $0.00filing
17 Jun 2026filed 18 Jun 2026OABI OmniAboption or derivative · Life-science toolsSEC FORM 4 Code A—40,000 at $0.00filing
17 Jun 2026filed 18 Jun 2026OABI OmniAboption or derivative · Life-science toolsSEC FORM 4 Code A—40,000 at $0.00filing
17 Jun 2026filed 18 Jun 2026OABI OmniAbLife-science toolsSEC FORM 4 Code M—20,000filing
1 Nov 2025filed 3 Nov 2025OABI OmniAboption or derivative · Life-science toolsSEC FORM 4 Code M—17,769 at $0.00filing
1 Nov 2025filed 3 Nov 2025OABI OmniAbLife-science toolsSEC FORM 4 Code M—17,769filing
17 Jun 2025filed 18 Jun 2025OABI OmniAboption or derivative · Life-science toolsSEC FORM 4 Code M—20,000 at $0.00filing
17 Jun 2025filed 18 Jun 2025OABI OmniAboption or derivative · Life-science toolsSEC FORM 4 Code A—20,000 at $0.00filing
17 Jun 2025filed 18 Jun 2025OABI OmniAboption or derivative · Life-science toolsSEC FORM 4 Code A—40,000 at $0.00filing
17 Jun 2025filed 18 Jun 2025OABI OmniAbLife-science toolsSEC FORM 4 Code M—20,000filing
8 May 2025filed 12 May 2025ALNY Alnylam Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—1,558 at $0.00filing
8 May 2025filed 12 May 2025ALNY Alnylam PharmaceuticalsBiotechnologySEC FORM 4 Code A—775 at $0.00filing
1 Nov 2024filed 1 Nov 2024OABI OmniAboption or derivative · Life-science toolsSEC FORM 4 Code M—17,769 at $0.00filing
1 Nov 2024filed 1 Nov 2024OABI OmniAbLife-science toolsSEC FORM 4 Code M—17,769filing
18 Jun 2024filed 21 Jun 2024OABI OmniAboption or derivative · Life-science toolsSEC FORM 4 Code M—20,000 at $0.00filing
18 Jun 2024filed 21 Jun 2024OABI OmniAboption or derivative · Life-science toolsSEC FORM 4 Code A—20,000 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

No trade we could place in a sector.

Related people

Amechi Ekeke NwachukuChief Operating Officer · Chief Operating Officer at OmniAb, filing Form 4 there in the last year
John L. HigginsDirector · Director at OmniAb, filing Form 4 there in the last year
Jennifer R. CochranDirector · Director at OmniAb, filing Form 4 there in the last year
Philip J. GotwalsDirector · Director at OmniAb, filing Form 4 there in the last year
Steven C. CrousePresident - Diag & Spatial Bi · Director at OmniAb, filing Form 4 there in the last year